← Back to Clinical Trials
Recruiting NCT07074639

NCT07074639 Cognitive-Motor Exergame Training in Frail Adults

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07074639
Status Recruiting
Phase
Sponsor Eleftheria Giannouli
Condition Aging
Study Type INTERVENTIONAL
Enrollment 344 participants
Start Date 2025-06-16
Primary Completion 2027-05-31

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age N/A
Study Type INTERVENTIONAL
All Conditions
Interventions
Personalized, home-based motor-cognitive exergame trainingOtago Exercise Program

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 344 participants in total. It began in 2025-06-16 with a primary completion date of 2027-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This international multicentre pragmatic randomized controlled trial (RCT) aims to evaluate the effectiveness of personalized, home-based cognitive-motor training using exergames in improving cognitive and motor functions in frail adults. A total of 344 frail participants from five European countries will be enrolled. Participants in the intervention group will engage in a personalized exergame program, while the control group will follow the Otago Exercise Program. Both groups will undergo 12 weeks of training. The primary outcome is balance, a critical component of functional independence and fall prevention, and a common denominator affected in both physical and cognitive frailty. Secondary outcomes including cognitive and motor fall-risk factors, fall incidence, cost-effectiveness, and psychosocial outcomes.

Eligibility Criteria

Inclusion Criteria: * 50 years and older * Fried Frailty Phenotype score 3 or higher and/or MoCA score between 10-25 * Must be able to give informed consent * Access to internet and a TV/large screen at home Exclusion Criteria: * Mobility limitations (e.g., severe arthritis or lower extremity amputation) * Cognitive limitations (e.g., advanced Alzheimer's disease, frontotemporal/Lewy body/vascular dementia) * Sensory limitations (e.g., color-blindness, complete hearing loss and neuropathy causing significant loss of sensation) * Psychiatric limitations (e.g., acute, or uncontrolled affective disorders) * Comorbidities that would impair their ability to engage in the training * Simultaneous participation in other clinical trials/intervention studies * Inability to understand game instructions and play the games safely, based on judgement of a therapist

Contact & Investigator

Central Contact

Eleftheria Giannouli, PhD

✉ eleftheria.giannouli@hest.ethz.ch

📞 +41 44 633 90 58

Principal Investigator

Eleftheria Giannouli, PhD

PRINCIPAL INVESTIGATOR

ETH Zurich

Frequently Asked Questions

Who can join the NCT07074639 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, studying Aging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07074639 currently recruiting?

Yes, NCT07074639 is actively recruiting participants. Contact the research team at eleftheria.giannouli@hest.ethz.ch for enrollment information.

Where is the NCT07074639 trial being conducted?

This trial is being conducted at Zurich, Switzerland.

Who is sponsoring the NCT07074639 clinical trial?

NCT07074639 is sponsored by Eleftheria Giannouli. The principal investigator is Eleftheria Giannouli, PhD at ETH Zurich. The trial plans to enroll 344 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology